FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204753499> ?p ?o ?g. }

• W3204753499 endingPage "S1143" @default.
• W3204753499 startingPage "S1143" @default.
• W3204753499 abstract "Since SARS-CoV-2 infection heavily affects vulnerable populations including those with immune suppression, it is of special value to study clinical course, treatment outcomes, and immunity in patients (pts) with hematological (hem) malignancies. CHRONOS19 is an ongoing observational study in adult pts (≥18 years) with hem diseases (malignant or non-malignant) and COVID-19 in Russia. This web-based registry collected de-identified data from 15 centers all over the country at 30, 90, and 180 days after lab-confirmed or suspected (based on CT and/or clinical symptoms) COVID-19 diagnosis. The primary endpoint was 30-day all-cause mortality. As of data cut-off on April 14, 2021, 626 pts were enrolled in the study; 562 were eligible for primary endpoint assessment, n (%): M/F 271 (48%) / 291 (52%), median age 56 [18-90] years, malignant disease in 516 (92%) pts, among them induction phase / relapse or refractory / remission / NA in 180 (35%) / 120 (23%) / 187 (36%) / 29 (6%) pts. Thirty-day all-cause mortality in pts with hem malignancies was 19%; 83% of deaths were due to COVID-19 complications. No increase of hem disease relapse rate after COVID-19 was observed at Day 90 or Day 180, although 180-day data was still not mature at the time of analysis. IgG to SARS-CoV-2 was detected in 84% of pts with hem malignancies (167/199). The highest rate of detected antibody immunity was found in pts with chronic myeloproliferative neoplasms (100%; 13/13), HL (100%; 12/12), and multiple myeloma (97%; 34/35), the lowest – in pts with CLL (62%; 8/13) and NHL (60%; 6/10 and 56%; 10/18 for low-grade and high-grade lymphoma, respectively). igG detection rate in CD20+ lymphoma (60%) was significantly lower than in HL or T-cell lymphoma (p=0.004). Pts with ECOG 0-2 throughout the disease had a high rate of antibody immunity (90%; 104/116) vs. those with ECOG 3-4 at the time of COVID-19 diagnosis (77.5%; 31/40) or with worsening of ECOG to 3-4 during the disease (78%; 36/46). Five cases of SARS-CoV-2 re-infection were described. Pts with hem malignancies and COVID-19 have higher mortality than the general population. Low post-disease antibody immunity to SARS-CoV-2 and cases of re-infection may justify vaccination of these pts and warrant further research." @default.
• W3204753499 created "2021-10-11" @default.
• W3204753499 creator A5000756185 @default.
• W3204753499 creator A5000837595 @default.
• W3204753499 creator A5002077604 @default.
• W3204753499 creator A5007077067 @default.
• W3204753499 creator A5009453463 @default.
• W3204753499 creator A5024001377 @default.
• W3204753499 creator A5028351915 @default.
• W3204753499 creator A5035012803 @default.
• W3204753499 creator A5037423548 @default.
• W3204753499 creator A5044776670 @default.
• W3204753499 creator A5047045249 @default.
• W3204753499 creator A5048104251 @default.
• W3204753499 creator A5052005638 @default.
• W3204753499 creator A5056017457 @default.
• W3204753499 creator A5072047436 @default.
• W3204753499 creator A5077089081 @default.
• W3204753499 creator A5077933082 @default.
• W3204753499 creator A5080998304 @default.
• W3204753499 creator A5087884311 @default.
• W3204753499 creator A5090838558 @default.
• W3204753499 date "2021-09-01" @default.
• W3204753499 modified "2023-09-30" @default.
• W3204753499 title "1590P Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies" @default.
• W3204753499 doi "https://doi.org/10.1016/j.annonc.2021.08.1583" @default.
• W3204753499 hasPublicationYear "2021" @default.
• W3204753499 type Work @default.
• W3204753499 sameAs 3204753499 @default.
• W3204753499 citedByCount "0" @default.
• W3204753499 crossrefType "journal-article" @default.
• W3204753499 hasAuthorship W3204753499A5000756185 @default.
• W3204753499 hasAuthorship W3204753499A5000837595 @default.
• W3204753499 hasAuthorship W3204753499A5002077604 @default.
• W3204753499 hasAuthorship W3204753499A5007077067 @default.
• W3204753499 hasAuthorship W3204753499A5009453463 @default.
• W3204753499 hasAuthorship W3204753499A5024001377 @default.
• W3204753499 hasAuthorship W3204753499A5028351915 @default.
• W3204753499 hasAuthorship W3204753499A5035012803 @default.
• W3204753499 hasAuthorship W3204753499A5037423548 @default.
• W3204753499 hasAuthorship W3204753499A5044776670 @default.
• W3204753499 hasAuthorship W3204753499A5047045249 @default.
• W3204753499 hasAuthorship W3204753499A5048104251 @default.
• W3204753499 hasAuthorship W3204753499A5052005638 @default.
• W3204753499 hasAuthorship W3204753499A5056017457 @default.
• W3204753499 hasAuthorship W3204753499A5072047436 @default.
• W3204753499 hasAuthorship W3204753499A5077089081 @default.
• W3204753499 hasAuthorship W3204753499A5077933082 @default.
• W3204753499 hasAuthorship W3204753499A5080998304 @default.
• W3204753499 hasAuthorship W3204753499A5087884311 @default.
• W3204753499 hasAuthorship W3204753499A5090838558 @default.
• W3204753499 hasBestOaLocation W32047534991 @default.
• W3204753499 hasConcept C126322002 @default.
• W3204753499 hasConcept C159654299 @default.
• W3204753499 hasConcept C203014093 @default.
• W3204753499 hasConcept C203092338 @default.
• W3204753499 hasConcept C2776364478 @default.
• W3204753499 hasConcept C2779341262 @default.
• W3204753499 hasConcept C535046627 @default.
• W3204753499 hasConcept C71924100 @default.
• W3204753499 hasConcept C8891405 @default.
• W3204753499 hasConcept C90924648 @default.
• W3204753499 hasConceptScore W3204753499C126322002 @default.
• W3204753499 hasConceptScore W3204753499C159654299 @default.
• W3204753499 hasConceptScore W3204753499C203014093 @default.
• W3204753499 hasConceptScore W3204753499C203092338 @default.
• W3204753499 hasConceptScore W3204753499C2776364478 @default.
• W3204753499 hasConceptScore W3204753499C2779341262 @default.
• W3204753499 hasConceptScore W3204753499C535046627 @default.
• W3204753499 hasConceptScore W3204753499C71924100 @default.
• W3204753499 hasConceptScore W3204753499C8891405 @default.
• W3204753499 hasConceptScore W3204753499C90924648 @default.
• W3204753499 hasLocation W32047534991 @default.
• W3204753499 hasLocation W32047534992 @default.
• W3204753499 hasLocation W32047534993 @default.
• W3204753499 hasOpenAccess W3204753499 @default.
• W3204753499 hasPrimaryLocation W32047534991 @default.
• W3204753499 hasRelatedWork W2035492084 @default.
• W3204753499 hasRelatedWork W2043455657 @default.
• W3204753499 hasRelatedWork W2057948995 @default.
• W3204753499 hasRelatedWork W2164219360 @default.
• W3204753499 hasRelatedWork W2435227317 @default.
• W3204753499 hasRelatedWork W3017822181 @default.
• W3204753499 hasRelatedWork W3032210197 @default.
• W3204753499 hasRelatedWork W4283821855 @default.
• W3204753499 hasRelatedWork W4381570565 @default.
• W3204753499 hasRelatedWork W573847062 @default.
• W3204753499 hasVolume "32" @default.
• W3204753499 isParatext "false" @default.
• W3204753499 isRetracted "false" @default.
• W3204753499 magId "3204753499" @default.
• W3204753499 workType "article" @default.